Navigation Links
Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
Date:11/7/2008

PHILADELPHIA, Nov. 7 /PRNewswire/ -- Data from an investigational, open-label, randomized study assessing extended dosing regimens of PROCRIT(R) (Epoetin alfa) in treating anemia in subjects with Stages 3 - 4 chronic kidney disease (CKD) were presented today at the American Society of Nephrology 41st Annual Meeting.

All three dosing groups, including the FDA-approved three-times-per-week (TIW) regimen, plus once-a-week (QW) and once-every-two-weeks (Q2W) investigational regimens, achieved a mean final hemoglobin (Hb) within the range of 11.0 - 11.9 g/dL. Based on the increases in Hb, the QW and Q2W investigational regimens were statistically non-inferior to the TIW regimen (lower limits of 95 percent confidence intervals [CIs] within the non-inferiority margin of -1 g/dL).

The percent of subjects with Hb exceeding 11.9 g/dL during the first 22 weeks of treatment was higher in the TIW group (86.2 percent) than in the QW (78.4 percent) and Q2W (71.2 percent) groups; the median per-subject frequency of Hb exceeding 11.9 g/dL was 6, 4 and 3 times for the TIW, QW and Q2W groups, respectively.

In the first 22 weeks of treatment, the proportion of subjects experiencing serious adverse events (SAEs) was 15 percent in the TIW group, compared with 22 percent in both the QW and Q2W groups. During the entire 44 weeks of treatment, the proportion of subjects experiencing SAEs was 29, 33 and 33 percent in the TIW, QW and Q2W groups, respectively. The number of subjects with investigator-confirmed thromboembolic vascular events (TVEs) over the first 22 weeks was 2 in the TIW, 2 in the QW and 3 in the Q2W groups; over 44 weeks, these numbers were 2, 5 and 8 in the TIW, QW and Q2W groups, respectively. The number of subjects who died during the first 22 weeks was 0 in the TIW, 6 in the QW and 3 in the Q2W groups. Over 44 weeks, 4, 6 and 4 subjects died, respectively. None of the deaths were considered related to the study drug.

"These data provide
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today ... trial of,KW-3902, an adenosine A1 receptor antagonist in ... heart failure (CHF),that indicate a strong trend toward ... KW-3902 experienced a higher rate of,improvement in dyspnea, ...
... Results Presented at the 12th Congress of ... 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... EHA in Vienna, Austria, showed positive responses ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
(Date:11/27/2014)... November 27, 2014 “LAB.C” was featured on ... the latest and coolest technology products available to consumers. Mallory ... product review and shared with viewers the company ... and Android devices. , Consumers love portability and functionality. ... Cable Case for the iPhone5 and 5S has a portable ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... Marietta, GA (PRWEB) November 27, 2014 "The ... the whole month of December is full of laughter as ... Tandy Wilson won by making a sweater from scratch. " ... lit Christmas tree, and if that weren't ridiculous enough, the ... on top. , For those interested in participating this ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 Ethane ... has announced it will provide a 10% Christmas discount on ... month of December. The discount offer will begin on 1 ... 2014. , About this offer, a PPC professional working ... for all, especially for small businesses, as this big discount ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... problem drinkers using alcohol to cope with personal problems ... drinking into adulthood, a recent study suggests. , The ... are still high-risk drinkers by age 34 may have ... development that typically occurs during college, including the ability ...
... 24 Conseco, Inc. (NYSE: CNO ) ... existing $911.8 million senior secured credit agreement. Banc ... in connection with the amendment. The amendment, which ... in the current repayment schedule, is expected to provide ...
... "Hangin, Out With My Baby," ... with their newborns, infants and toddlers, will be distributed free ... hospitals throughout the U.S. Starting today with a live concert ... CDs will be given away this year by participating hospitals.Arranged ...
... Cancer Society Cancer Action Network, the American Heart Association, ... Kids applaud Senator Frank Lautenberg of New Jersey,s call ... authority and immediately remove e-cigarettes from the market. ... publications during the past few weeks saying that e-cigarettes ...
... help metropolitan public health agencies,prepare to deliver essential ... or natural disease outbreak has succeeded in improving,the ... Corporation study. , Researchers found that the federal ... areas, appears to have improved,agencies, ability to rapidly ...
... experts at The University of Nottingham have shown that ... the quality of life for many community-based dialysis patients. ... journal Biomaterials , have shown that the catheter ... wider variety of pathogens and protect Continuous Ambulatory Peritoneal ...
Cached Medicine News:Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
... general-purpose agarose, like the entire line of ... grade. This ensures that DNA recovered from ... compromising quality. Certified molecular biology agarose is ... molecular weight, resulting in a gel structure ...
Medicine Products: